(Stroke. 2005;36:1140.)
© 2005 American Heart Association, Inc.
Original Contributions |
From the Department of Neurosurgery, University of Illinois at Chicago.
Correspondence to Sepideh Amin-Hanjani, MD, Department of Neurosurgery, Neuropsychiatric Institute (MC 799), University of Illinois at Chicago, 912 S Wood St, Chicago, IL 60612-7329. E-mail hanjani{at}uic.edu
| Abstract |
|---|
|
|
|---|
Methods All patients with symptomatic VBD at our institution are evaluated by a standard protocol including quantitative magnetic resonance angiography (QMRA). Patients are stratified on the basis of the presence or absence of distal flow compromise. Those with low distal flow are offered intervention (surgical or endovascular); all patients receive standard medical therapy. We reviewed the clinical outcome of patients managed with this protocol from 1998 to 2003.
Results Follow-up was available for 47 of 50 patients over a mean interval of 28 months. Stroke and combined stroke/transient ischemic attack free survival at 2 years was calculated using the KaplanMeier curve. Patients with normal distal flow (n=31) had an event-free survival of 100% and 96%, respectively. Comparatively, patients with low distal flow (n=16) experienced a 71% and 53% event-free survival, demonstrating a significantly higher risk of recurrent ischemia (P=0.003). Patients with low flow who subsequently underwent treatment (n=12) had an 82% event-free survival. Cox proportional hazards analysis demonstrated that flow status affected event-free survival regardless of covariates.
Conclusions Patients with symptomatic VBD demonstrating low distal flow on QMRA appear to have a high risk of stroke; conversely, those with normal flow seem to have a benign course and may be optimally managed with medical therapy alone.
Key Words: blood flow stenosis stroke transient ischemic attack vertebrobasilar insufficiency
| Introduction |
|---|
|
|
|---|
We sought to determine whether a management algorithm for symptomatic VBD consisting of quantitative hemodynamic assessment could identify patients at high risk for stroke and guide the need for intervention. Existing modalities for evaluating hemodynamic insufficiency have been unsatisfactory for detection of posterior circulation compromise.6 As an alternative modality, phase-contrast quantitative magnetic resonance angiography (QMRA) is a noninvasive tool for measuring blood flow in intracranial vessels. At our institution, we incorporated QMRA analysis into our diagnostic work-up of all patients presenting with vertebrobasilar insufficiency (VBI). Patients with symptomatic VBD are considered for intervention if evidence of flow compromise is present and treated medically otherwise. We reviewed the subsequent risk of stroke in the presence or absence of distal flow compromise because this may define a population of patients most likely to benefit from revascularization.
| Methods |
|---|
|
|
|---|
Patients were considered to have VBI if they demonstrated characteristic symptoms of dizziness or vertigo, transitory bilateral motor or sensory deficits, ataxia or clumsiness, dysarthria, dysphagia, or transitory diplopia or other visual symptoms. Isolated dizziness was not felt to be adequate to diagnose VBI. Angiography was recommended in all patients with MRA findings consistent with >50% stenosis. The majority of patients (84%) underwent angiography. If angiography could not be performed for medical reasons such as renal failure or was declined by the patient, a high-resolution 3-T MRA was used to make the determination of stenosis. For the purposes of this study, if angiography or MRA reports did not specify the percentage of stenosis, descriptive terms such as "severe" or "high-grade" stenosis were used as acceptable evidence of >50% stenosis. After evaluation, those patients with >50% vertebrobasilar stenosis or occlusion on angiography or MRA and symptoms of VBI were characterized as having symptomatic VBD.
Transient ischemic attack (TIA) was defined as a transient focal neurological deficit attributed to ischemia lasting <24 hours. A stroke was defined as a focal neurological deficit lasting >24 hours attributable to cerebral infarction. The occurrence of these events was determined by the multidisciplinary neurovascular group. Follow-up evaluation was routinely recommended at 6-month intervals but occurred more or less frequently dependent on the individual case. Follow-up was performed primarily through clinic visits but also by phone contact if the patient lived remotely or failed to appear for a clinic appointment. A review of the patients condition and clinical data were routinely performed by our multidisciplinary group at the time of follow-up.
Blood Flow Measurements
Patients with symptomatic VBD all underwent quantitative flow measurements of the extracranial and intracranial arteries using QMRA. The technique of blood flow quantification by QMRA has been described previously.7 The technique is now implemented and enhanced in commercially available software called the NOVA (Noninvasive Optimal Vessel Analysis) system (VasSol, Inc.).
Management Algorithm
The flow measurements of the posterior circulation were interpreted on the basis of the algorithm shown in Figure 1 to represent low or normal flow distal to the site of VBD. Flows in specific vessels were felt to be reduced if they were >20% lower than the lower limit of baseline normative ranges available for those vessels (supplemental Table I, available online at http://www.strokeaha.org). This threshold was based on existing literature on cerebral blood flow and perfusion assessment that indicates that blood flow reduction in the range of 20% to 25% in distal flow is correlated with ischemia.911 The vessels used to designate flow status were those that reflect the distal territory of the vertebrobasilar tree, namely the basilar artery (BA) itself, and the posterior cerebral arteries (PCAs). If the PCA was found to be anatomically fetal, it no longer represented a distal outflow of the vertebrobasilar system and was therefore not considered in designation of flow status. On the basis of our criteria for flow reduction, the BA was designated as reduced if flow was measured to be <120 cc/min, and the PCAs if flows were <40 cc/min. For a designation of "low flow," the BA and PCAs had to be reduced. In borderline cases, for example, with 1 PCA below threshold and the other maintained, additional criteria were used, as outlined in Figure 1.
|
|
Patients were recommended medical therapy alone or intervention (surgery or endovascular therapy) coupled with medical therapy based on the designation of their flow status. Patients with normal distal flow as outlined by the algorithm were felt to be experiencing primarily either embolic phenomenon or, more commonly, small vessel disease. All these patients were managed medically with anticoagulants or antiplatelet agents. Patients with reduced distal flow were felt to be experiencing a regional flow compromise, which would be amenable to flow augmentation by angioplasty/stenting or surgical bypass procedures. These patients were offered intervention in addition to medical therapy. Patients were followed clinically, and episodes of TIA or new/recurrent stroke were noted.
Statistical Analysis
Ischemic events in the territory of the posterior circulation were used as the primary end point. Stroke and combined stroke/TIA were evaluated as separate events. Survival was defined as the interval between presentation and stroke or stroke and TIA. Stroke and stroke/TIA-free survival was estimated with the KaplanMeier curve at 24 months. The event-free survival is provided with 95% CI as an indicator of the precision of the estimate. Clinical variables between groups were compared using unpaired 2-tailed Students t test or the chi square test where appropriate. Univariate analysis to compare survival curves between groups was performed with the log-rank test. The effect of age, gender, lesion location (intracranial versus extracranial; basilar versus other), stroke as presenting symptom, degree of stenosis (occlusion versus >80% versus 50% to 80%), and type of medical therapy after diagnosis (anticoagulant versus antiplatelet versus both) was examined. Cox proportional hazards analysis was used to assess the effect of covariates showing significance of P<0.10 on univariate analysis. All analyses were performed with STATA (Intercooled version 6; Stata Corporation).
| Results |
|---|
|
|
|---|
|
Management Algorithm
Of the 50 patients, 33 (66%) showed normal distal flow and were managed medically. Seventeen patients demonstrated low flow and were offered intervention, 12 subsequently underwent revascularization, and 5 deferred treatment. Follow-up was available in 47 of the 50 patients, as outlined below, over an average period of 27.9 months (range 4 to 65 months; median 23 months).
Normal Distal Flow (n=31)
Thirty-one patients in the normal distal flow category were managed with medical therapy, with either anticoagulants, antiplatelet agents, or both. Treatment regimens often changed during the period of follow-up, with a tendency to switch to antiplatelet agents alone over time. During the follow-up period, none of these patients experienced new or recurrent strokes. Two patients experienced TIAs 6 and 38 months after initial presentation. Over a total of 80.2 person years of follow-up, this resulted in a 0% stroke and 2.5% stroke/TIA rate per person year.
Low Distal Flow (n=16)
Sixteen patients with significant flow reduction in the vertebrobasilar system were candidates for treatment. Twelve patients underwent intervention and were censored from analysis of stroke rates at the time of intervention; their subsequent course is described in the section below. In 4 cases, intervention was refused by the patient, or other medical comorbidities made intervention high risk. All patients were receiving anticoagulants or antiplatelets. During the 10.6 person years of follow-up, 2 patients experienced strokes, and an additional patient experienced recurrent TIA, resulting in an 18.9% stroke and 28.3% stroke/TIA rate per person year.
Low Distal Flow With Intervention (n=12)
In the 12 patients who underwent intervention, endovascular therapy was offered if technically feasible, and angioplasty/stenting was performed in 3 cases. The remaining 9 cases were treated with a variety of surgical revascularization procedures, including extracranialintracranial bypass and carotidvertebral transposition. Two patients experienced strokes after therapy: 1 perioperatively after a failed superficial temporal artery-PCA bypass graft, and another 6 months after angioplasty. Over 18.4 person years of follow-up, this resulted in a 10.9% yearly ischemic event rate.
Risk of Stroke and TIA
Stroke and combined stroke/TIA-free survival was examined in the 3 groups of patients using the KaplanMeier method (Figure 2). Patients with normal distal flow (n=31) had a stroke and stroke/TIA-free survival of 100% and 96% (95% CI, 77% to 99%), respectively, at 24 months. Comparatively, patients with low distal flow (n=16) had a 71% (CI, 23% to 92%) and 53% (CI, 12% to 83%) event-free survival, demonstrating a significantly higher risk of recurrent ischemia (P=0.003). Patients with low flow after treatment (n=12) had an 82.5% (CI, 46% to 95%) stroke and stroke/TIA-free survival.
|
For patients with intracranial VBD (n=34), stroke-free survival was 93% at 24 months overall. The risk was focused in the low flow group, which demonstrated 66% stroke-free survival compared with 100% stroke-free in the normal flow group.
On univariate analysis of the medically treated patients, only flow status (low versus normal distal flow; P=0.003) and presence of basilar disease (P=0.03) significantly affected combined stroke/TIA-free survival. Multivariate analysis with Cox proportional hazards analysis demonstrated that flow status affected event-free survival regardless of lesion location (P=0.03).
| Discussion |
|---|
|
|
|---|
Using QMRA to assess posterior circulation hemodynamics, we identified a population with symptomatic VBD and normal distal flow that demonstrated a 100% stroke-free survival at 2 years with medical management alone. Existing retrospective studies have estimated the risk associated with intracranial stenosis (50% to 99%) to be particularly high, at 10% to 15% per year.3,4 Mouffarij et al reported an 80% stroke-free survival at 2 years in a retrospective study of patients with distal vertebral artery or BA stenosis of
50%.16 The recent study by Qureshi et al of 102 patients with symptomatic intracranial VBD (>50% stenosis) demonstrated that 14% of patients experienced recurrent stroke, with a stroke-free survival of 72% at 2 years.3 In comparison, our group of medically managed patients with intracranial VBD (n=34) had a better overall 2-year stroke-free survival of 92%, which likely reflects a preselection of patients felt to be at high risk (because of low flow), for intervention. The stroke risk was concentrated in the low flow patients, whereas the normal flow patients had a 100% stroke-free survival at 2 years. Therefore, even in a population typically defined as high risk, assessment of distal flow can distinguish a subset with a more benign course. Although proximal vertebral disease is generally felt to carry a lower risk of recurrent ischemia,17 our analysis suggests that it is the presence or absence of distal large vessel flow compromise rather than the location of the disease that is most pertinent in predicting stroke risk. However, the small number of stroke end points in this study may lessen our power to detect the significance of other potential predictors of stroke risk.
Reduced basilar flow rates measured by magnetic resonance have been described previously in patients with VBI.18 Our results demonstrate that patients can be stratified on this basis, and those without distal flow compromise are at significantly lower stroke risk, even when compared with published stroke rates in similar patients.3,4,16 Defining appropriate candidates for intervention is especially important given that the efficacy and risks of revascularization strategies have not been fully characterized. Endovascular therapy with angioplasty and stenting, particularly for intracranial disease, has become increasingly feasible over the last decade but has been tempered by concerns for distal embolization of plaque material or fatal vessel rupture.19,20 Technical success rates are reported to range from 83% to 100% for both extracranial21,22 and intracranial disease,2326 with 88% to 93% of patients remaining symptom-free within a year of the intervention.22,26 However, despite recent series suggesting reduced complication rates,2325 stroke and death rates up to 35% are still reported.27,28 The efficacy of angioplasty in long-term stroke reduction and long-term patency is not well established. Surgical revascularization using bypass carries higher risks and lower patency rates than that seen from anterior circulation bypass, with an approximate 20% risk of major morbidity/mortality and success rates of 75% to 90%.29,30
Because of the retrospective nature of this analysis, there is a potential for selection, recall, and ascertainment bias. For example, a patient with a fatal ischemic event may be more likely to lack follow-up. However, only 3 patients were lost to follow-up (2 normal flow and 1 low flow), and their outcomes do not qualitatively change the results. The lack of angiographic confirmation of stenosis in all cases is another potential source of selection bias if MRA underestimates stenosis and angiography is performed less frequently in patients designated as normal flow. However, the majority of patients did undergo confirmatory angiography, and high-quality 3-T MRA was used otherwise. Furthermore, repeat analysis excluding patients without angiography yields equivalent results. Recall bias is another potential concern because intervals between follow-ups often span periods of 6 to 12 months. Although patients may not accurately recall TIAs, it is unlikely that a stroke would be under-reported. Ascertainment of end point events was not performed in a blinded fashion, which may also lead to bias, but determination of ischemic events was made in a standard fashion by a multidisciplinary group. Other identifiable and unidentified factors may also alter the stroke risk and are difficult to address in this study. For example, the type of antithrombotic/antiplatelet therapy was frequently altered by the referring physician during the course of a patients follow-up. The heterogeneity of treatments and changes over time may affect stroke risk in ways that are not accounted for in our analysis. Consequently, the results need to be interpreted cautiously. A prospective standardized application of our management algorithm would be the next step in verifying these results.
| Conclusion |
|---|
|
|
|---|
Blood Flow Measurements (available online only at http://www.strokeaha.org)
An axial 2D or 3D time-of-flight MRA is performed first. The acquired images are then transmitted to a PC workstation where the NOVA software (VasSol, Inc.) is used to create a rotating 3D surface rendering of the vasculature, including the circle of Willis, using a marching cube algorithm7 (Figure I, top). From the scan line (Figure I, bottom) calculated by a line-fitting algorithm,7 a double-oblique scan is performed using gated 2D phase-contrast magnetic resonance imaged perpendicular to the vessel axis. A flow report including the mean volumetric flow rate (cc/min) on each vessel of interest is created using the NOVA software. All the images were acquired with the use of 1.5-T or 3-T GE MRI scanner (General Electric). Flow measurements performed on 1.5-T or 3-T scanners are equivalent.8
|
| Footnotes |
|---|
Received March 7, 2005; accepted March 16, 2005.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Zhao, S. Amin-Hanjani, S. Ruland, A.P. Curcio, L. Ostergren, and F.T. Charbel Regional Cerebral Blood Flow Using Quantitative MR Angiography AJNR Am. J. Neuroradiol., September 1, 2007; 28(8): 1470 - 1473. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Weintraub, A. Khoury, S. Amin-Hanjani, and F. T. Charbel Use of Quantitative Magnetic Resonance Angiography to Stratify Stroke Risk in Symptomatic Vertebrobasilar Disease * Response: Stroke, November 1, 2005; 36(11): 2341 - 2342. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |